| 摘要 |
<p>Methods and compositions are disclosed utilizing optically pure (-) lansoprazole for the treatment of ulcers in humans while substantially reducing the concomitant liability of adverse effects associated with the racemic mixture of lansoprazole. The optically pure (-) isomer is also useful for the treatment of gastroesophageal reflux. (-) Lansoprazole is an inhibitor of H+ release and is therefore useful in the treatment of other conditions related to gastric hypersecretion such as Zollinger-Ellison Syndrome.</p> |
